MEREDITH SLAYTER: Open Payments
NPI 1932468428 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,094 in 98 payments from 18 companies in 2025. Trend: 2023 $1,967 · 2024 $1,915 · 2025 $2,094
Food & beverage: $2,060Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $245 |
| GlaxoSmithKline, LLC. | 13 | $213 |
| GENZYME CORPORATION | 9 | $191 |
| Verona Pharma, Inc. | 8 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Amgen Inc. | 7 | $157 |
| Insmed, Inc. | 7 | $128 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $124 |
| Grifols USA, LLC | 5 | $99 |
Products named: DUPIXENT, TEZSPIRE, Ohtuvayre, GLASSIA, NUCALA, Arikayce, XIFAXAN, Prolastin-C Liquid.
Industry payments across IN — which companies pay providers there.
